A Systematic Review on Clinical Features and Prognostic Significance of V600E Versus Non-V600E Braf Mutations in Colorectal Cancer

Abstract

Objective: Colorectal cancer is the leading cause of global mortality. Recently, there has been interest in the molecular targets for treatment of cancer. B-rapidly expanded fibrosarcoma (BRAF) mutations, particularly V600E and nonV600E, are the common mutations with diverse clinical presentations and prognosis. The present systematic review was conducted to assess the clinical features and prognostic value of these two BRAF mutations. Methods: Six retrospective and prospective cohort studies which met the inclusion and exclusion criteria, were included in the present systematic review. These studies were published 2017 onwards. The studies included a total of 19373 patients. The studies were included after a thorough search of online databases and Google search. Results: The prevalence of BRAF mutation ranged from 5 to 10% with V600E BRAF mutation being more prevalent. The colorectal cancer associated with V600E BRAF mutation showed female predilection with older age at presentation. There was a predominance of right-sided colon cancer. It was also associated with shorter median overall survival and disease-free survival, along with poor response to treatment. Conclusion: The present systematic review highlights the different demographic and clinical presentations of the colorectal cancer associated with V600E BRAF mutation and with non-V600E BRAF mutations. Colorectal cancers with non-V600E BRAF mutation are associated with a better response to therapy and longer survival. Thus, the subtyping of mutation should be done to predict the behavior of these cancers and their prognosis.